ArticleAllergy2025
Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study.
Article in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.Allergy · 2026Guideline
- Scoping review: biomarkers in chronic inducible urticaria.Frontiers in immunology · 2026Pooled it
- Dupilumab in patients with cold urticaria: Results from a phase 3 trial.The journal of allergy and clinical immunology. Global · 2026Article
- Factors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study.American journal of clinical dermatology · 2026Article
- Exploring the Disease Duration of Urticaria and Associated Determinants in Primary Care.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Advancements and challenges in the management of chronic inducible urticaria.Frontiers in immunology · 2026Review
- Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- An Overview of Chronic Spontaneous Urticaria: Diagnosis, Management, and Treatment.Allergy, asthma & immunology research · 2025Review
- Article
- Current treatment practices and efficacy in solar urticaria: insights from a patient survey.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
backgroundLong-term data on the effectiveness and safety of omalizumab for chronic inducible urticaria (CIndU) in large populations are lacking.
objectiveTo evaluate the effectiveness, safety, estimated omalizumab treatment duration and its predictors, as well as differences between CIndU subtypes, in a large long-term CIndU cohort.
methodsA multinational multicenter study was conducted at 14 specialized urticaria centres (UCAREs), including all CIndU patients ever treated with omalizumab from 2009 until July 2022. Kaplan-Meier survival and regression analyses were performed.
resultsAcross 234 CIndU patients (55% female; mean age 37 years), 76% (n = 178) had standalone CIndU and 24% (n = 56) had predominant CIndU plus minor CSU, with an observation period up to 13 years. Most CIndU patients (73%, n = 145/200 with available data on response) had complete/good response to omalizumab treatment, without significant differences between CIndU subtypes. Sixty-two (26%) patients discontinued omalizumab; due to well-controlled disease (47%, n = 29), ineffectiveness (34%, n = 21), side effects (3%, n = 2), combination of ineffectiveness and side effects (3%, n = 2) and other reasons (13%, n = 8). The median estimated omalizumab treatment duration exceeded 5 years (54% drug survival at 5 years) and was mostly determined by well-controlled disease. Higher age predicted a lower chance to discontinue omalizumab due to well-controlled disease (HR 0.969, 95%CI 0.945-0.995). CIndU subtype and presence of minor CSU were not related to response and time until omalizumab discontinuation for any reason.
conclusionOmalizumab is highly effective and safe in CIndU patients, with long estimated treatment duration mainly reflecting long disease duration. Our data show omalizumab's high potential as treatment in any subtype of CIndU and support its clinical use for these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.